Inhibitors of the phosphatidylinositol-@-kinase / protein kinase B/mammalian target of rapamycin ( PI@K/AKT/mTOR ) pathway can overcome endocrine resistance in estrogen receptor ( ER ) - positive breast cancer , but companion diagnostics indicating PI@K/AKT/mTOR activation and consequently endocrine resistance are lacking .